Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McCollough steps down as St Jude group president

This article was originally published in Clinica

Executive Summary

Joseph McCollough has stepped down as group president of St Jude Medical and is retiring from the company. He first joined the firm in 1994 as regional sales director for its cardiac rhythm management (CRM) division – he took on the role of group president in January 2008, overseeing St Jude's US and international divisions and its corporate brand and global marketing functions. Subsequent to his departure, Michael Rousseau, current group president for CRM, will assume responsibility for the US division. Mr Rousseau, who Morgan Stanley analyst David Lewis described as "the natural choice" in succession, had previously ran St Jude's US operations from 2002-08. It is anticipated that his experience could potentially boost the firm's performance in the US, where its CRM and atrial fibrillation franchises have faltered over the last two quarters, noted Mr Lewis. The international division, which is managed by Denis Gestin, will report directly to St Jude president, CEO and chairman Daniel Starks.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts